



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/828,935	
			Filing Date	04/21/2004	
			First Named Inventor	Gorenstein et al.	
			Art Unit	1639	
			Examiner Name	T.D. Vessundof	
Sheet	1	of	2	Attorney Docket Number	UTMB:1024

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
T.D.		WO 00 47774 A1	08/17/2000	Janjic, et al.		
		WO 92 14842 A	09/03/1992	Toole, et al.		
		WO 92 14843	09/03/1992	Toole, et al.		
		WO 93 08296 A	04/29/1993	Hoke, et al.		
		WO 96 19572 A	06/27/1996	Hybridon		
		WO 96 41019 A1	08/17/2000	Janjic, et al.		
		WO 99 31275	06/24/1999	Gold, et al.		

Examiner Signature	T.D. Vessundof	Date Considered	12/26/06
-----------------------	----------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/828,935
		Filing Date	04/21/2004
		First Named Inventor	Gorenstein et al.
		Art Unit	1635
		Examiner Name	T. D. Wessendy
Sheet 2 of 2	Attorney Docket Number	UTMB:1024	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
T. D. W.		ANTSYPOVICH, ET AL. (1998) Cross-linked DNA duplexes: Exonuclease stability and interaction with the nucleic transcription factor of the κ light-chain enhancer (NF- κ B).	
		BIELINSKA, ET AL. (1990) Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides, <i>Science</i> , Vol. 250, pg. 997-1000.	
		KHALED, ET AL. (1998) Use of Phosphorothioate-Modified Oligodeoxynucleotides to Inhibit NF- κ B Expression and Lymphocyte Function, <i>Clinical Immunology and Immunopathology</i> , Vol. 86, No. 2, pp. 170-179.	
		KING, ET AL., (1998) Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers. <i>Biochemistry</i> , 37, 16489-16493.	
		KUNSCH, ET AL. (1992) Selection of Optimal κ B/Rel DNA-Binding Motifs: Interaction of Both Subunits of NF- κ B with DNA is Required for Transcriptional Activation, <i>Molecular and Cellular Biology</i> , October 1992, Vol. 12, No. 10, p. 4412-4421.	
		LEBRUSKA, ET AL. (1999) Selection and Characterization of an RNA Decoy for Transcription Factor NF- κ B ⁺ , <i>Biochemistry</i> , 38, 3168-3174.	
		MORISHITA, ET AL. (1997) In vivo transfection of cis element "decoy" against nuclear factor- κ B binding site prevents myocardial infarction, <i>Nature Medicine</i> , Vol. 3, No. 8, p. 894-899.	
		NAKAMAYE, ET AL. (1988) Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside α -thiotriphosphates, <i>Nucleic Acids Research</i> , Vol. 16, No. 21.	
		SHARMA, ET AL. (1996) Transcription Factor Decoy Approach to Decipher the Role of NF- κ B in Oncogenesis, <i>Anticancer Research</i> , 16:61-70.	
		STEC, ET AL. (1997) Deoxyribonucleoside 3'-O-(2-Thio- and 2-Oxo-"spiro"-4,4-pentamethylene-1,3,2-oxathia phospholane)s: Monomers for Stereocontrolled Synthesis of Oligo(deoxyribonucleoside phosphorothioate)s and Chimeric PS/PO Oligonucleotides ³ , <i>J. Am. Chem. Soc.</i> , 120, 7156-7167.	
		UHLMANN, ET AL. (1997) Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation, <i>Antisense & nucleic Acid Drug Development</i> , 7:345-350.	
		ZON, GERALD (1988) Oligonucleotide Analogues as Potential Chemotherapeutic Agents. <i>Pharmaceutical Research</i> , Vol. 5, No. 9, pp. 539-549.	

Examiner Signature	T. D. W.	Date Considered	12/26/06
--------------------	----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Bead Bound Combinatorial Oligonucleoside Phosphorothioate and Phosphorodithioate Aptamer Libraries						
<p>Application Number: 10/272509 10/828,935</p> <p>Confirmation Number: 8419</p> <p>First Named Applicant: David Gorenstein</p> <p>Attorney Docket Number: UTMB1013</p> <p>Search string: (6544776 or 6503715 or 6458543 or 6423493 or 6242246 or 5874219 or 5853984 or 5804445 or 5795721 or 5763595 or 5734041 or 5705337 or 5661134 or 5660985 or 5639873 or 5635488 or 5620963 or 5607923 or 5602000 or 5599797 or 5587361 or 5576302 or 5397698 or 5218088 or 20030162216).pn.</p> <p>US Patent Documents</p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p>							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	6544776	2003-04-08	Gold			
<input type="checkbox"/>	2	6503715	2003-01-07	Gold			
<input type="checkbox"/>	3	6458543	2002-10-01	Gold			
<input type="checkbox"/>	4	6423493	2002-07-23	Gorenstein			
<input type="checkbox"/>	5	6242246	2001-06-05	Gold			
<input type="checkbox"/>	6	5874219	1999-02-23	Rava			
<input type="checkbox"/>	7	5853984	1998-12-29	Davis			
<input type="checkbox"/>	8	5804445	1998-09-08	Brasier			
<input type="checkbox"/>	9	5795721	1998-08-18	Rabin			
<input type="checkbox"/>	10	5763595	1998-06-09	Gold			
<input type="checkbox"/>	11	5734041	1998-03-31	Just			
<input type="checkbox"/>	12	5705337	1998-01-06	Gold			
<input type="checkbox"/>	13	5661134	1997-08-26	Cook			
<input type="checkbox"/>	14	5660985	1997-08-26	Pieken			
<input checked="" type="checkbox"/>	15	5639873	1997-06-17	Barascut			

<input checked="" type="checkbox"/>	16	5635488	1997-06-03	Cook
<input type="checkbox"/>	17	5620963	1997-04-15	Cook
<input type="checkbox"/>	18	5607923	1997-03-04	Cook
<input type="checkbox"/>	19	5602000	1997-02-11	Hyman
<input type="checkbox"/>	20	5599797	1997-02-04	Cook
<input type="checkbox"/>	21	5587361	1996-12-24	Cook
<input type="checkbox"/>	22	5576302	1996-11-19	Cook
<input type="checkbox"/>	23	5397698	1995-03-14	Goodman
<input checked="" type="checkbox"/>	24	5218088	1993-06-08	Gorensein


US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	20030162216	2003-08-28	Gold			

Signature

Examiner Name	Date
T. D. J.	12/20/06



INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Complete if Known

Attorney Docket Number	UTMB:1013
------------------------	-----------

2

This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
			Application Number	10/272,509
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	10/16/2002
			First Named Inventor	Gorenstein et al.
			Art Unit	1645 39
			Examiner Name	T. D. Wissendy
(Use as many sheets as necessary)			Attorney Docket Number	UTMB:1013
Sheet	2	of	2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANTSYPOVICH, ET AL. (1998) Cross-linked DNA duplexes: Exonuclease stability and interaction with the nucleic transcription factor of the κ light-chain enhancer (NF- κ B).	
		BIELINSKA, ET AL. (1990) Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides, <i>Science</i> , Vol. 250, pg. 997-1000.	
		KHALED, ET AL. (1998) Use of Phosphorothioate-Modified Oligodeoxynucleotides to inhibit NF- κ B Expression and Lymphocyte Function, <i>Clinical Immunology and Immunopathology</i> , Vol. 86, No. 2, pp. 170-179.	
		KING, ET AL., (1998) Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers. <i>Biochemistry</i> , 37, 16489-16493.	
		KUNSCH, ET AL. (1992) Selection of Optimal κ B/Rel DNA Binding Motifs: Interaction of Both Subunits of NF- κ B with DNA is Required for Transcriptional Activation, <i>Molecular and Cellular Biology</i> , October 1992, Vol. 12, No. 10, p. 4412-4421.	
		LEBRUSKA, ET AL. (1999) Selection and Characterization of an RNA Decoy for Transcription Factor NF- κ B ⁺ , <i>Biochemistry</i> , 38, 3168-3174.	
		MORISHITA, ET AL. (1997) In vivo transfection of cis element "decoy" against nuclear factor- κ B binding site prevents myocardial infarction, <i>Nature Medicine</i> , Vol. 3, No. 8, p. 894-899.	
		NAKAMAYE, ET AL. (1988) Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside α -thiotriphosphates, <i>Nucleic Acids Research</i> , Vol. 16, No. 21.	
		SHARMA, ET AL. (1996) Transcription Factor Decoy Approach to Decipher the Role of NF- κ B in Oncogenesis, <i>Anticancer Research</i> , 16:61-70.	
		STEC, ET AL. (1997) Deoxyribonucleoside 3'-O-(2-Thio- and 2-Oxo-"spiro"-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: Monomers for Stereocontrolled Synthesis of Oligo(deoxyribonucleoside phosphorothioate)s and Chimeric PS/PO Oligonucleotides ⁵ , <i>J. Am. Chem. Soc.</i> , 120, 7156-7167.	
		UHLMANN, ET AL. (1997) Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation, <i>Antisense & nucleic Acid Drug Development</i> , 7:345-350.	
		ZON, GERALD (1988) Oligonucleotide Analogues as Potential Chemotherapeutic Agents. <i>Pharmaceutical Research</i> , Vol. 5, No. 9, pp. 539-549.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.